Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.
Conditions
Interventions
Remdesivir
Remdesivir placebo
Locations
1
China
Bin Cao
Beijing, Beijing Municipality, China
Start Date
February 6, 2020
Primary Completion Date
March 30, 2020
Completion Date
April 10, 2020
Last Updated
April 15, 2020
NCT07221162
NCT06082518
NCT06631287
NCT05141058
NCT06679140
NCT06417762
Lead Sponsor
Capital Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions